292 related articles for article (PubMed ID: 35265072)
1. CLCF1 Is a Novel Potential Immune-Related Target With Predictive Value for Prognosis and Immunotherapy Response in Glioma.
Jiang Y; Ji Q; Long X; Wang P; Tu Z; Zhang X; Zhu X; Huang K; Li J
Front Immunol; 2022; 13():810832. PubMed ID: 35265072
[TBL] [Abstract][Full Text] [Related]
2. Pyroptosis: a novel signature to predict prognosis and immunotherapy response in gliomas.
He G; Chen Z; Zhuo S; Tang J; Hao W; Yang K; Yang C
Hum Cell; 2022 Nov; 35(6):1976-1992. PubMed ID: 36129672
[TBL] [Abstract][Full Text] [Related]
3. Deciphering the role of QPCTL in glioma progression and cancer immunotherapy.
Liu Y; Lu S; Sun Y; Wang F; Yu S; Chen X; Wu LL; Yang H; Shi Y; Zhao K
Front Immunol; 2023; 14():1166377. PubMed ID: 37063864
[TBL] [Abstract][Full Text] [Related]
4. ITGB2 as a prognostic indicator and a predictive marker for immunotherapy in gliomas.
Xu H; Zhang A; Han X; Li Y; Zhang Z; Song L; Wang W; Lou M
Cancer Immunol Immunother; 2022 Mar; 71(3):645-660. PubMed ID: 34313821
[TBL] [Abstract][Full Text] [Related]
5.
Qu S; Liu J; Wang H
Front Immunol; 2021; 12():648416. PubMed ID: 33889156
[TBL] [Abstract][Full Text] [Related]
6. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
7. Optimization of cancer immunotherapy through pyroptosis: A pyroptosis-related signature predicts survival benefit and potential synergy for immunotherapy in glioma.
Zeng Y; Cai Y; Chai P; Mao Y; Chen Y; Wang L; Zeng K; Zhan Z; Xie Y; Li C; Zhan H; Zhao L; Chen X; Zhu X; Liu Y; Chen M; Song Y; Zhou A
Front Immunol; 2022; 13():961933. PubMed ID: 35990696
[TBL] [Abstract][Full Text] [Related]
8. Molecular and clinical characterization of PARP9 in gliomas: A potential immunotherapeutic target.
Xu H; Chai S; Wang Y; Wang J; Xiao D; Li J; Xiong N
CNS Neurosci Ther; 2020 Aug; 26(8):804-814. PubMed ID: 32678519
[TBL] [Abstract][Full Text] [Related]
9. Molecular and clinical features of a potential immunotherapy target ELK3 in glioma.
Xu H; Zhang L; Gao J; Wang J; Wang Y; Xiao D; Chai S
Medicine (Baltimore); 2022 Jul; 101(30):e29544. PubMed ID: 35905257
[TBL] [Abstract][Full Text] [Related]
10. Functional characterization of TSPAN7 as a novel indicator for immunotherapy in glioma.
Chen L; Liu H; Li Y; Lin X; Xia S; Wanggou S; Li X
Front Immunol; 2023; 14():1105489. PubMed ID: 36845098
[TBL] [Abstract][Full Text] [Related]
11. ABCD3 is a prognostic biomarker for glioma and associated with immune infiltration: A study based on oncolysis of gliomas.
Li J; Zhang Y; Qu Z; Ding R; Yin X
Front Cell Infect Microbiol; 2022; 12():956801. PubMed ID: 35959373
[TBL] [Abstract][Full Text] [Related]
12. Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas.
Li Y; Feng Y; Luo F; Peng G; Li Y
Front Immunol; 2022; 13():1089792. PubMed ID: 36726969
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 Pattern Provides a New Scoring System and Predicts the Prognosis and Immune Therapeutic Response in Glioma.
Jiang F; Lu DF; Zhan Z; Yuan GQ; Liu GJ; Gu JY; Sun XO; Wang Z
Cells; 2022 Dec; 11(24):. PubMed ID: 36552760
[TBL] [Abstract][Full Text] [Related]
14. Ferroptosis-related gene signature correlates with the tumor immune features and predicts the prognosis of glioma patients.
Hu Y; Tu Z; Lei K; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34726238
[TBL] [Abstract][Full Text] [Related]
15. Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour microenvironment in lower-grade glioma.
Cai J; Hu Y; Ye Z; Ye L; Gao L; Wang Y; Sun Q; Tong S; Yang J; Chen Q
Front Immunol; 2022; 13():1011757. PubMed ID: 36325335
[TBL] [Abstract][Full Text] [Related]
16. ECM2, a prognostic biomarker for lower grade glioma, serves as a potential novel target for immunotherapy.
Cheng X; Liu Z; Liang W; Zhu Q; Wang C; Wang H; Zhang J; Li P; Gao Y
Int J Biochem Cell Biol; 2023 May; 158():106409. PubMed ID: 36997057
[TBL] [Abstract][Full Text] [Related]
17. Circadian Regulation Patterns With Distinct Immune Landscapes in Gliomas Aid in the Development of a Risk Model to Predict Prognosis and Therapeutic Response.
Tian R; Li Y; Shu M
Front Immunol; 2021; 12():797450. PubMed ID: 35069579
[TBL] [Abstract][Full Text] [Related]
18. CNN3 in glioma: The prognostic factor and a potential immunotherapeutic target.
Xu H; Chai SS; Lv P; Wang JJ
Medicine (Baltimore); 2021 Nov; 100(46):e27931. PubMed ID: 34797350
[TBL] [Abstract][Full Text] [Related]
19. Integrative Analysis of Inflammatory Response-Related Gene for Predicting Prognosis and Immunotherapy in Glioma.
Zhao Z; Zheng B; Zheng J; Zhang Y; Jiang C; Nie C; Jiang X; Yao D; Zhao H
J Mol Neurosci; 2023 Aug; 73(7-8):608-627. PubMed ID: 37488455
[TBL] [Abstract][Full Text] [Related]
20. A
Rafii S; Ghouzlani A; Naji O; Ait Ssi S; Kandoussi S; Lakhdar A; Badou A
Int J Mol Sci; 2023 Apr; 24(7):. PubMed ID: 37047660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
